P8RI
Based on 1 Customer Validation
P8RI (D-P8RI) is a biomimetic peptide of CD31 and a CD31 agonist. P8RI binds to the juxtamembrane amino acid sequence of the ectodomain of CD31, shows an immunosuppressive effect through restoration of the CD31 inhibitory pathway.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté : 99.49%
- CAS No.: 2147724-76-1
- Formule: C51H77N13O9
- Masse moléculaire:1016.24
-
Stockage:
Sealed storage, away from moisture and light.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
Voir tous les produits spécifiques à Isoform VEGFR
More
Activité biologique
Description
In Vitro
P8RI (D-P8RI) was designed as a retro-inverso peptide with all-D-amino acids allowing to maintain bioactivity and to confer resistance towards plasma proteases[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Apo E -/- mice (male, 28-week-old) implanted with Ang II-releasing pumps (a model of experimental acute aortic dissection and intramural hematoma (ADIM))[3]
-
Dosage:2.5 mg/kg
-
Administration:Subcutaneous injection; daily from 7 to 28 (after the implantation of the osmotic pump delivering Ang II)
-
Result:Aneurysmal transformation was significantly reduced.
Chemical Information
-
CAS No. 2147724-76-1
-
Appearance Solid
-
Masse moléculaire 1016.24
-
Formule C51H77N13O9
-
Color White to off-white
-
Synonyms
D-P8RI
-
Sequence
d(Lys-Trp-Pro-Ala-Leu-Phe-Val-Arg)
-
Sequence Shortening
d(KWPALFVR)
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Sealed storage, away from moisture and light
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Solvant et solubilité
In Vitro:
H2O : ≥ 100 mg/mL (98.40 mM)
DMSO : 100 mg/mL (98.40 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Pureté et documentation
-
Fiche technique (277 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Diaz-Rodriguez S, et al. Coronary stent CD31-mimetic coating favours endothelialization and reduces local inflammation and neointimal development in vivo. Eur Heart J. 2021;42(18):1760-1769. [Content Brief]
[2]. Sannier A, et al. A CD31-Derived Peptide Prevents the Development of Antibody-Mediated Lesions in a Rat Model of Aortic Allograft. Transplant Proc. 2021;53(2):746-749. [Content Brief]
[3]. Andreata F, et al. Macrophage CD31 Signaling in Dissecting Aortic Aneurysm. J Am Coll Cardiol. 2018;72(1):45-57. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O / DMSO | 1 mM | 0.9840 mL | 4.9201 mL | 9.8402 mL | 24.6005 mL |
| 5 mM | 0.1968 mL | 0.9840 mL | 1.9680 mL | 4.9201 mL | |
| 10 mM | 0.0984 mL | 0.4920 mL | 0.9840 mL | 2.4600 mL | |
| 15 mM | 0.0656 mL | 0.3280 mL | 0.6560 mL | 1.6400 mL | |
| 20 mM | 0.0492 mL | 0.2460 mL | 0.4920 mL | 1.2300 mL | |
| 25 mM | 0.0394 mL | 0.1968 mL | 0.3936 mL | 0.9840 mL | |
| 30 mM | 0.0328 mL | 0.1640 mL | 0.3280 mL | 0.8200 mL | |
| 40 mM | 0.0246 mL | 0.1230 mL | 0.2460 mL | 0.6150 mL | |
| 50 mM | 0.0197 mL | 0.0984 mL | 0.1968 mL | 0.4920 mL | |
| 60 mM | 0.0164 mL | 0.0820 mL | 0.1640 mL | 0.4100 mL | |
| 80 mM | 0.0123 mL | 0.0615 mL | 0.1230 mL | 0.3075 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
P8RI Related Classifications
HY-P3325 Related Classifications
Powered by Bioz